Kintara Therapeutics to Present at the Q4 Investor Summit Virtual Conference on November 17, 2021
Kintara Therapeutics (Nasdaq: KTRA) will present at the Q4 Investor Summit Conference on November 17, 2021, at 1:15 p.m. ET. CEO Robert E. Hoffman will provide a corporate overview and is available for one-on-one meetings throughout the event. The company is focused on developing novel therapies for rare cancers, with two Phase 3-ready treatments: VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. Kintara's VAL-083 has shown clinical promise across multiple cancers, while REM-001 displays an 80% efficacy in prior studies.
- None.
- None.
SAN DIEGO, Nov. 11, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces today that its Chief Executive Officer, Robert E. Hoffman, will present a corporate overview at the Q4 Investor Summit Conference, which is being held virtually on November 16 – 17, 2021.
Mr. Hoffman will deliver his corporate presentation on November 17, 2021 at 1:15 p.m.ET.
Mr. Hoffman will be available for one-on-one meetings throughout the conference.
Register HERE to watch the presentation.
About Kintara
Located in San Diego, California, Kintara (Nasdaq: KTRA) is dedicated to the development of novel cancer therapies for patients with rare unmet medical needs. Kintara is currently developing two Phase 3-ready therapeutics, VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).
VAL-083 is a "first-in-class", small-molecule, bifunctional alkylating agent that crosses the blood-brain-barrier and has a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM.
REM-001 is a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy of
For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and Linkedin.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company's operations and clinical trials; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2021, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.
CONTACTS
Investors
CORE IR
516-222-2560
ir@coreir.com
Media
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-to-present-at-the-q4-investor-summit-virtual-conference-on-november-17-2021-301422038.html
SOURCE Kintara Therapeutics
FAQ
What is Kintara Therapeutics' stock symbol?
When will Kintara Therapeutics present at the Q4 Investor Summit?
Who is presenting for Kintara Therapeutics at the Investor Summit?
What are the key products being developed by Kintara Therapeutics?
What is the efficacy of REM-001 in clinical trials?
